COVID-19, vaccination against SARS-CoV-2 and antiviral treatment in rheumatic diseases - revised opinion of the Czech Society for Rheumatology

1. Šenolt L. a kolektiv Výboru České Revmatologické Společnosti. Stanovisko České revmatologické společnosti k léčbě revmatických onemocnění a očkování v kontextu infekce SARS-CoV-2. Čes. Revmatol. 2020; 28(4): 197–205.

2. Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79(7): 851–858.

3. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version2. Arthritis Rheumatol 2020; 72(9): e1–e11.

4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52(1): 53–61.

5. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2020; annrheumdis-2020-218946.

6. Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared
with the general population: a systematic review and meta-analysis. Rheumatol Int 2021; 41(5): 851–861.

7. Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS--CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic
and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis 2022; 81(3): 422–432.

8. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9(6): 622–42.

9. Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory
rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford) 2021; 60(SI): SI59–SI67.

10. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with
rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; 80(4): 527–538.

11. Bower H, Frisell T, Di Giuseppe D, et al; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 2021; 80(8): 1086–1093.

12. Strangfeld A, Schäfer M, Gianfrancesco MA, et al; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician–reported registry. Ann Rheum Dis 2021; 80(7): 930–942.

13. D’Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared
to the general population: a US multicenter, comparative cohort study. Arthritis Rheumatol 2021; 73(6): 914–920.

14. Rutter M, Lanyon PC, Grainge MJ, et al. COVID-19 infection, admission and death amongst people with rare autoimmune rheumatic
disease in England. Results from the RECORDER project. Rheumatology (Oxford) 2021: keab794.

15. Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti--inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul 2021; 81: 100818.

16. Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021; 3(10): e724– e736.

17. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory
rheumatic diseases treated with rituximab. Ann Rheum Dis 2021; 80(5): e67.

18. Sparks JA, Wallace ZS, Seet AM, et al; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic
or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the covid-19 Global Rheumatology
Alliance physician registry. Ann Rheum Dis 2021; 80(9): 1137–1146.

19. Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14(3): 898–907.

20. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20(4): 102792.

21. Tang KT, Hsu BC, Chen DY. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol 202112; 12: 645013.

22. Foret T, Dufrost V, Salomon Du Mont L, et al. Systematic review of antiphospholipid antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep 2021; 23(8): 65.

23. Schenker HM, Hagen M, Simon D, Schett G, Manger B. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. Rheumatology (Oxford) 20215; 60(1): 479–480.

24. Zacharias H, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of Covid 19. Autoimmun Rev 2021; 20(9): 102883.

25. Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021; 40(7): 2611–2619.

26. Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges forp healthcare professionals. Arch Med Res 2021; 52(6): 575–581.

27. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28: 583–590.

28. Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol 2021: https://doi.org/10.1007/s12016-021-08848-3

29. Metyas S, Chen C, Aung T, Ballester A, Cheav S. Rheumatologic manifestations of post SARS-CoV-2 infection: a Case Series. Curr Rheumatol Rev 2022; doi: 10.2174/1573397118666220211155 716

30. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20(11): e276–e288.

31. Ruddy JA, Connolly CM, Boyarsky BJ, et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80(10): 1351–1352.

32. Seror R, Camus M, Salmon JH, et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIKSFR Registry. Lancet Rheumatol 2022; 4(1): e8–e11.

33. Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 2021; 3(11): e778– e788.

34. Sieiro Santos C, Calleja Antolin S, Moriano Morales C, et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open 2022; 8(1): e001898. 3

5. Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021; 80(10): 1322–1329.

36. Krasselt M, Wagner U, Nguyen P, et al. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford) 2022: keac089.

37. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician–reported registry. Ann Rheum Dis 2021; annrheumdis-2021-221490.

38. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA 2022; 327(7): 639–651.

39. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence – 25 U.S. Jurisdictions, April 4 – December 25, 2021. MMWR Morb Mortal Wkly Rep 2022; 71(4): 132–138.

40. Barbhaiya M, Levine JM, Bykerk VP, Jannat–Khah D, Mandl LA. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis 2021; 80(10): 1352–1354.

41. Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 2022; 24(1): 21.

42. Connolly CM, Ruddy JA, Boyarsky BJ, et al. Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 2022; 74(1): 28–32.

43. https://www.rheumatology.org/Portals/0/Files/covid-19-Vaccine- Clinical-Guidance-Rheumatic-Diseases-Summary.pdf

44. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARSCoV- 2: the November 2021 update. Ann Rheum Dis 2022; annrheumdis- 2021-222006.

45. Bijlsma JW; EULAR COVID-19 Task Force. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis 2022; annrheumdis-2021-221965.

46. Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7(1): e001464.

47. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 2022; 19: 1–6. https:// doi.org/10.1038/s41591-021-01678-y

48. van de Veerdonk FL, Giamarellos–Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med 2022; 28(1): 39–50.

49. Borio LL, Bright RA, Emanuel EJ. A national strategy for COVID-19 medical countermeasures: Vaccines and therapeutics. JAMA 2022; 327(3): 215–216.

50. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest 2020; 130(12): 6409–6416.